Longevium
Dubai longevity and preventive medicine group with three clinics and a research arm. It announced a USD 7 million first round in August 2026 to build an AI longevity research laboratory at Dubai Science Park.
Industry: Longevity and preventive medicine | Location: Dubai, United Arab Emirates | Total Funding: USD 7M
About Longevium
Longevium is a Dubai-based longevity healthcare company. It runs a network of three clinics in the emirate, located in Jumeirah, Jumeirah Lake Towers and Jumeirah Village Circle. The clinics employ close to 100 physicians and specialists and, according to TechScoop's reporting, have treated more than 30,000 patients. The company was founded by Dr Ksenia Butova, who has described its long-term mission around a future in which healthy human lifespans could stretch to as much as 200 years, an ambition TechScoop flagged as speculative and aspirational rather than a near-term promise.
The company has disclosed one funding round: USD 7 million raised in what was reported as its first funding round, with coverage describing it as seed funding. The identity of the investors behind the round has not been disclosed. The September 2026 roundup of the biggest MENA startup rounds since LEAP 2026 lists the raise among the smaller but notable deals of the period.
The money is earmarked for a Longevity AI Research Laboratory at Dubai Science Park, due to open in the fourth quarter of 2026. TechScoop notes that the lab is a research and development centre rather than another clinic, which marks a move from delivering services toward developing underlying technologies. It is intended to combine artificial intelligence, biomedical research and clinical science to build tools that predict health risks, measure biological age and support healthier lifespans. The research agenda includes AI-powered digital twins, which are virtual patient models used for continuous monitoring and predictive risk analysis, alongside regenerative medicine, tissue engineering, advanced cell therapies, robotic diagnostics and smart medical devices.
The existing clinics are the company's main asset for this plan. Their patient base provides an established clinical environment for the long-term data collection and validation that AI health research depends on, something many AI-health startups lack. TechScoop describes the business as an operating clinic network with real patients rather than a pre-revenue concept, though it does not publish revenue figures.
The raise sits within Dubai's wider push to position itself as a global hub for longevity medicine, including the establishment of a dedicated Dubai Longevity Authority, and within a broader pattern of Gulf capital flowing into advanced healthcare and AI. TechScoop's healthcare coverage names Longevium as the clearest case of explicit AI use among the funded Gulf health companies it reviewed, and places it alongside regional health-tech activity such as Abu Dhabi's Prepaire Labs.
TechScoop also raised caveats. The undisclosed investor list limits how much can be read into the round, longevity medicine ranges from rigorous preventive care to costly unproven interventions, and premium longevity clinics have faced criticism for selling tests and treatments whose long-term benefits are not established. The publication's view is that the underlying move, a clinic network investing in genuine research capability inside a government-backed ecosystem, is credible provided the science meets a higher standard than the marketing around it.
Leadership
- Dr Ksenia Butova, Founder
- Sergey Shayakhmetov, Co-founder